P. Kraiczy et al., Further characterization of complement regulator-acquiring surface proteins of Borrelia burgdorferi, INFEC IMMUN, 69(12), 2001, pp. 7800-7809
The three genospecies Borrelia burgdorferi, Borrelia garinii, and Borrelia
afzelii, all causative agents of Lyme disease, differ in their susceptibili
ties to human complement-mediated lysis. We recently reported that serum re
sistance of borrelias correlates largely with their ability to bind the hum
an complement regulators FHL-1/ reconectin and factor H. To date, two compl
ement regulator-acquiring-proteins (CRASP-1 and CRASP-2) have been identifi
ed in serum-resistant B. afzelii isolates (P. Kraiczy, C. Skerka, NI. Kirsc
hfink, V. Brade, and P. F. Zipfel, Eur. J. Immunol. 31:1674-1684, 2001). He
re, we present a comprehensive study of the CRASPs detectable in both serum
-resistant and intermediate serum-sensitive B. afzelii and B. burgdorferi i
solates. These CRASPs were designated according to the genospecies either a
s BaCRASPs, when derived from B. afzelii, or as BbCRASPs, for proteins iden
tified in B. burgdorferi isolates. Each borrelial isolate expresses distinc
t CRASPs that can be differentiated by their mobility and binding phenotype
s. A detailed comparison reveals overlapping and even identical binding pro
files for BaCRASP-1 (27.5 kDa), BbCRASP-1 (25.9 kDa), and BbCRASP-2 (23.2 k
Da), which bind FHL-1/reconectin strongly and interact weakly with factor I
I. In contrast, two B. afzelii proteins (BaCRASP-4 [19.2 kDa] and BaCRASP-5
[22.5 kDa]) and three B. burgdorferi proteins (BbCRASP-3 [19.8 kDa], BbCRA
SP-4 [18.5 kDa], and BbCRASP-5 [17.7 kDa]) bind factor II but not FHL-1/rec
onectin. Most CRASPs bind both human immune regulators at their C-terminal
ends. Temperature-dependent upregulation of CRASPs (BaCRASP-1, BaCRASP-2, a
nd BaCRASP-5) is detected in low-passage borrelias cultured at 33 or 37 deg
reesC compared with those cultured at 20 degreesC. The characterization of
the individual CRASPs on the molecular level is expected to identify new vi
rulence factors and potential vaccine candidates.